President Donald Trump recently signed an executive order aimed at lowering prescription costs, which, on the surface, appears to be an ambitious attempt to rein in America’s high drug spending, David Wainer of The Wall Street Journal reports. Yet, Trump’s announcement lacked policy detail and the pathways to overhauling drug spending in the U.S. mostly run through congress. As with much of his other deals, Trump’s threats can give way to negotiated settlements with minor concessions that will allow him to declare victory. Publicly traded drugmakers include AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), Novo Nordisk (NVO), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Companies involved the sale of pharmaceuticals include CVS Health (CVS), Cigna (CI), UnitedHealth (UNH), Cardinal Health (CAH), McKesson (MCK) and Cencora (COR).
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- JPMorgan sees ‘most favored nation’ drug order facing ‘significant push back’
- Pharma Stocks Rally despite Trump’s Plan to Cut Drug Prices
- White House publishes Trump executive order aimed at lowering drug prices
- AstraZeneca’s Trixeo Aerosphere approved for use in UK with propellant
- Trump to sign executive order aimed at lowering drug prices